Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics Evaluation (ID: i827a) Survey

1.Sara, a 36-year-old female, presents on 6-month follow-up after initiating IL-5 antibiotic and continuing high-dose ICS. Baseline eosinophils were 374/µL and FeNO was 51 ppb. Her IgE level was 25 IU/ml and allergy skin tests were negative. She has no notable comorbidities or atopic history. She was diagnosed with asthma at age 27. She continues to experience symptoms 2-3x/week with 1 exacerbation in the last 6 months and is concerned about continued impact to daily activities. What would be the most appropriate next step?(Required.)

Continue the anti-IL-5 biologic and reassess in 3-6 months

Switch to a different IL-5 biologic

Switch to anti-IL-4 biologic

Switch to anti-IgE biologic

Discontinue biologic and prescribe OCS

2.How many patients with severe asthma do you manage per week?(Required.)

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

3.After participating in this activity, how confident are you in the management of patients with severe asthma in your practice?(Required.)

4.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

5.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

6.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)

Improved awareness of the unmet treatment needs in severe asthma

Better understanding of the limitations of conventional biologic therapies

Increased knowledge of the benefit of targeted therapeutic options for patients with severe asthma

Increased awareness of the primary upstream cytokines involved in severe asthma

Improved knowledge of the role of specific epithelial alarmins in inducing symptoms of severe asthma

Better able to appropriately incorporate therapies that target alarmins into individualized treatment regimens to meet the unmet needs of patients with severe asthma

Increased awareness of investigational and newly approved anti-alarmin therapies

Increased knowledge of clinical trial data for anti-alarmin agents and how to apply this data to clinical care

Improved ability to select the optimal anti-alarmin therapy for the individualized treatment of patients with severe asthma

7.What barriers do you see to making changes in your practice? Please select all that apply.(Required.)

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please explain)

11.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

12.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future severe asthma educational activities:

13.If you indicated that you perceived commercial bias or influence, please describe: